Pleiotropic effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia
Not Applicable
Completed
- Conditions
- patients with type 2 diabetes mellitus and hypercholesterolemia
- Registration Number
- JPRN-UMIN000007264
- Lead Sponsor
- niversity of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
patients with a history of stroke or ischemic heart disease during the previous 6 months patients with hepatopathy (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >80 IU/L) patients with nephropathy (serum creatinine >1.3 mg/dL) female patients who were pregnant or possibly pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint was specified as achievement of the target LDL-C level (<80 mg/dL).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the pleiotropic effects of pravastatin, atorvastatin, and rosuvastatin in type 2 diabetes and hypercholesterolemia patients?
How do the pleiotropic effects of pravastatin, atorvastatin, and rosuvastatin compare to standard-of-care statins in managing cardiovascular risk in type 2 diabetes?
Which biomarkers are associated with differential response to pravastatin, atorvastatin, or rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia?
What are the potential adverse events and management strategies for pravastatin, atorvastatin, and rosuvastatin in type 2 diabetes and hypercholesterolemia populations?
How do pravastatin, atorvastatin, and rosuvastatin's pleiotropic effects compare to other HMG-CoA reductase inhibitors in type 2 diabetes mellitus patients?